A Randomized, Multicentrique, Single-Blind, Observational Pilot Study To Evaluate Efficacy And Safety Of Pirdal Nasal Spray In Preventing Symptomatic Manifestation Of Disease In Covid-19 Proven Cases.

VITROBIO SAS0 个研究点目标入组 213 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1 Male or Female patients detected positive for Covid 19 by RT-PCR test and who have no or slight nasal /respiratory clinical signs at the time of recruitment.
•2 The patients aged between 18-70 at the time of screening.
•3 Patients who agreed not to self- medicate with other potential preventive ARI-antivirals. Ã¯â??Â· Not currently symptomatic with an acute respiratory illness
•4 Patients with Cooperative and understanding skills.
•5 Patient willing to provide written informed consent.
•6 Patient able to have internet access each day of the study to complete the online questionnaire
•7 Patients ready to abstain from using any drug other than Investigational Product for the treatment of the studied condition, except in emergencies, in which case the responsible party must be immediately notified. Patients with moderate hypertension or diabetes may be included in the study.

•Patients, who will meet any of the exclusion criteria, will not be included in the study.
•1 Hypersensitivity/History of allergy to any of the investigational products componants
•2 Any recent nasal surgery
•3 Abnormal structural narrowing of sinus passages such as Deviated Nasal Septum or other kind of anatomical obstruction
•4 Any unstable, serious co-existing medical condition including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to the Screening visit
•5 Clinical evidence of immunosuppression
•6 Patient under treatment of viral disease
•7 Patient with severe respiratory signs
•8 Patients +ve for serum antibodies
•9 Patients who have participated in other clinical studies less than 1 year prior to screening.

发起方